La vendita allo scoperto per ImmuCell dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di ImmuCell. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

ImmuCell (NASDAQ:ICCC) Azioni, Report sulle vendite allo scoperto

ImmuCell

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.

ImmuCell Corp

ImmuCell Corporation (Nasdaq:&nbsp;ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today&nbsp;announced preliminary, unaudited sales results for the third quarter of 2024, which ended September 30, 2024.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="6">Preliminary, Unaudited Total Sales Results: &nbsp;</td>
</tr>
<tr>
<td>2024</td>
<td>2023</td>
<td colspan="2">$ Increase</td>
<td colspan="1">% Increase</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>During the Three-Month Periods Ended September 30,</td>
<td>$6.0 million</td>
<td>$5.4 million</td>
<td colspan="2">$615,000</td>
<td>11%</td>
</tr>
<tr>
<td>During the Nine-Month Periods Ended September 30,</td>
<td>$18.7 million</td>
<td>$12.4 million</td>
<td colspan="2">$6.4 million</td>
<td>51%</td>
</tr>
<tr>
<td>During the Twelve-Month Periods Ended September 30,</td>
<td>$23.8 million</td>
<td>$16.3 million</td>
<td colspan="2">$7.6 million</td>
<td>46%</td>
</tr>
</tbody>
</table>
</figure>
 During the three-, nine- and twelve-month periods ended September 30, 2024, annualized production output was approximately 73%, 81% and 77%, respectively, of the Company's estimated full capacity of approximately $30 million per year.
As of September 30, 2024, the backlog of orders aggregated approximately $7.3 million. The Company believes that the current backlog reflects strong demand as distributors work to replenish their buffer stocks and as end-users place orders in advance of the first quarter calving season.
Since the first quarter of 2020, the Company has been providing a preliminary look at its unaudited top line results soon after the close of the quarter. The Company expects to continue providing this prompt, preliminary report on product sales until further notice going forward.

Earnings

News

Guidance

ICCC

ImmuCell Announces Preliminary Q3 Revenue Of $6M Up From $5.4M YoY

ImmuCell Sees Q2 $(0.20) Down From $(0.18) YoY; Product Sales $5.473M Up From $3.533M YoY

With U.S. stock futures trading mixed this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Manchester United Plc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MANU#NYSE">MANU</a>) to report a quarterly loss at 27 cents per share on revenue of $162.92 million before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Manchester United shares gained 1.6% to $16.19 in the after-hours trading session.</li>
<li>Kura Sushi USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRUS#NASDAQ">KRUS</a>) posted downbeat results for its third quarter on Tuesday. Kura Sushi shares fell 4.2% to $56.00 in the after-hours trading session.</li>
<li>Analysts are expecting PriceSmart, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSMT#NASDAQ">PSMT</a>) to post quarterly earnings at $1.01 per share on revenue of $1.21 billion. The company will release earnings after the markets close. PriceSmart shares gained 1% to $79.00 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a> 
<ul>
<li>ImmuCell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCC#NASDAQ">ICCC</a>) reported preliminary sales results for the second quarter. The company said it sees preliminary sales of $5.47 million up from $3.53 million in the year-ago period. ImmuCell shares climbed 8.9% to $4.67 in the after-hours trading session.</li>
<li>Analysts expect AZZ Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZZ#NYSE">AZZ</a>) to post quarterly earnings at $1.30 per share on revenue of $402.05 million. AZZ shares gained 2.7% to $77.00 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39690602/delta-air-lines-likely-to-report-lower-q2-earnings-here-are-the-recent-forecast-changes-from-wall-s">Delta Air Lines Likely To Report Lower Q2 Earnings; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
Photo courtesy: PriceSmart

Pre-Market Outlook

Markets

Trading Ideas

KRUS

MANU

PSMT

PriceSmart, Kura Sushi And 3 Stocks To Watch Heading Into Wednesday

WIIM

ImmuCell shares are trading higher after the company reported preliminary Q2 sales results.

ImmuCell Sees Prelim. Q2 Sales $5.47M Up From $3.53M YoY

ImmuCell Corporation (Nasdaq:&nbsp;ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today&nbsp;provided a regulatory update on the status of its product development initiative for Re-Tain&#xAE;.

Biotech

General

ImmuCell Updates Regulatory Status Of Product Development Initiative For Re-Tain

ImmuCell Reports $7.3M In Product Sales For Quarter Ended March 31, 2024

ImmuCell Anticipates No Change To Preliminary Sales Results For Q1 Ended March 31, 2024 That Were Disclosed On April 9

<h3>Gainers</h3>
<ul>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares rose 25.3% to $0.11 during Tuesday's after-market session. The company's market cap stands at $31.1 million. </li>
<li>aTyr Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFE#NASDAQ">LIFE</a>) shares rose 10.45% to $1.9. The company's market cap stands at $128.7 million. </li>
<li>Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) shares increased by 7.36% to $1.75. The market value of their outstanding shares is at $85.8 million. </li>
<li>ImmuCell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCC#NASDAQ">ICCC</a>) shares increased by 7.27% to $5.6. The market value of their outstanding shares is at $43.4 million. </li>
<li>Avenue Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) shares moved upwards by 6.46% to $0.16. The company's market cap stands at $6.9 million. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares increased by 5.34% to $1.38. The company's market cap stands at $47.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Apyx Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APYX#NASDAQ">APYX</a>) shares declined by 6.1% to $1.38 during Tuesday's after-market session. The company's market cap stands at $47.8 million. </li>
<li>NKGen Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) shares decreased by 6.11% to $1.23. The market value of their outstanding shares is at $27.5 million. </li>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) shares decreased by 5.95% to $1.74. The market value of their outstanding shares is at $11.4 million. </li>
<li>Medigus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGS#NASDAQ">MDGS</a>) stock declined by 5.62% to $2.52. The company's market cap stands at $4.7 million. </li>
<li>Novo Integrated Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVOS#NASDAQ">NVOS</a>) shares declined by 5.18% to $0.5. The market value of their outstanding shares is at $8.9 million. </li>
<li>Avalo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) stock fell 4.98% to $13.76. The company's market cap stands at $14.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

APYX

ATXI

AVTX

CRVS

JAGX

LIFE

MDGS

MTEM

NKGN

NVOS

12 Health Care Stocks Moving In Tuesday's After-Market Session

Total sales during the twelve-month period ended March 31, 2024 were&nbsp;33%&nbsp;more than the twelve-month period ended March 31, 2023.

ImmuCell Reports Preliminary, Unaudited Sales Results For Q1 2024 Of $7.3M, Up 111% Y/Y

ImmuCell Q4 2023 EPS $(0.15) Up From $(0.22) YoY; Product Sales $5.1M Up From $3.9M YoY

ACAD

ACHC

AESI

AHCO

AIRS

ALEC

ALHC

AMBA

AMBC

APLS

ARKO

ARQT

ARRY

ATEC

AXON

BCSF

BECN

BGFV

BMBL

BWXT

BYND

CAVA

CBRL

CIVI

CLDT

CLNE

CLVT

CMLS

COMP

CPNG

CRDO

CYTK

EBAY

EHTH

ESPR

FARO

FLYW

FOUR

FSLR

FULC

GDOT

GLPI

GMRE

GSX Techedu Inc. American Depositary Shares

GOTU

GPOR

HRZN

HSIC

HURN

ICFI

ICUI

IMAX

IMXI

INGN

INSE

IPAR

JAMF

KIND

KURA

KVYO

LAZR

LGND

LGVN

Earnings Scheduled For February 27, 2024

ImmuCell Sees Prelim. Q4 Sales $5.1M, 2023 Sales $17.5M

ImmuCell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCC#NASDAQ">ICCC</a>) reported quarterly losses of $(0.12) per share. This is a 50 percent decrease over losses of $(0.08) per share from the same period last year. The company reported $5.40 million in sales this quarter. This is a 12.53 percent increase over sales of $4.80 million the same period last year.

ImmuCell Q3 2023 Gaap EPS $(0.12) Down From $(0.08) YoY, Sales $5.40M Up From $4.80M YoY

AACG

ABOS

ACIC

ACOR

ACTG

AFYA

AGRO

AKTS

AMPS

ASTR

ASUR

ATEX

ATXS

AZTA

BAER

BIOR

BIOX

BWEN

CARA

CELC

CLSD

CPLP

CYCC

DCTH

DFLI

DMAC

DRRX

DXYN

EARN

EDBL

ELUT

EYEN

FFIE

FTRE

GENI

GEVO

GLAD

GRCL

GRND

HOFV

HROW

HSAI

ICAD

ICMB

IMCC

JRSH

KMDA

LICY

LUCD

LUNR

MBRX

MDAI

MITQ

MKFG

MNDY

MVLA

NABL

NVGS

NXGL

OCFT

OMQS

OPAL

OWLT

PLSE

PRSO

RBOT

RELI

ROIV

RVYL

SACH

SALM

SBLK

SKIN

SKYX

SLND

SMTI

SNDL

SOHU

SPRO

TBIO

THMO

TOVX

Earnings Scheduled For November 13, 2023

&nbsp;ImmuCell Corporation (Nasdaq:&nbsp;ICCC)&nbsp;(&ldquo;ImmuCell&rdquo; or the &ldquo;Company&rdquo;), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today&nbsp;announced preliminary, unaudited sales results for the&nbsp;third quarter&nbsp;of 2023, which ended September 30, 2023.
<table border="1" cellspacing="0" style="width:696.875px">
<tbody>
<tr>
<td colspan="17">Preliminary, Unaudited Total Sales Results:</td>
</tr>
<tr>
<td style="text-align:center">&nbsp;</td>
<td style="text-align:center">&nbsp;</td>
<td colspan="2">2023</td>
<td style="text-align:center">&nbsp;</td>
<td style="text-align:center">&nbsp;</td>
<td colspan="2">2022</td>
<td style="text-align:center">&nbsp;</td>
<td style="text-align:center">&nbsp;</td>
<td colspan="2">$ Increase 
			($ Decrease)</td>
<td style="text-align:center">&nbsp;</td>
<td style="text-align:center">&nbsp;</td>
<td colspan="2">% Increase 
			(% Decrease)</td>
<td style="text-align:center">&nbsp;</td>
</tr>
<tr>
<td style="width:259.625px">During the Three-Month Periods Ended September 30,</td>
<td style="text-align:left; width:6.875px">$</td>
<td style="width:71.8438px">5.40 million</td>
<td style="width:6.875px">$</td>
<td style="width:71.8438px">4.80 million</td>
<td style="text-align:left; width:6.875px">$</td>
<td style="text-align:right; width:69.625px">600,000</td>
<td style="text-align:right; width:47.4375px">13</td>
<td style="text-align:left; width:17.7969px">%</td>
</tr>
<tr>
		</tr>
<tr>
<td>During the Nine-Month Periods Ended September 30,</td>
<td>$</td>
<td style="text-align:right; white-space:nowrap">12.38 million</td>
<td>$</td>
<td>14.66 million</td>
<td style="text-align:left">$</td>
<td>(2.28 million</td>
<td style="text-align:left">)</td>
<td style="text-align:right">(16</td>
<td style="text-align:left">%)</td>
</tr>
<tr>
		</tr>
<tr>
<td style="text-align:left">During the Trailing Twelve-Month Periods Ended September 30,</td>
<td>$</td>
<td>16.29 million</td>
<td>$</td>
<td>20.10 million</td>
<td style="text-align:left">$</td>
<td>(3.81 million</td>
<td style="text-align:left">)</td>
<td style="text-align:right">(19</td>
<td style="text-align:left">%)</td>
</tr>
</tbody>
</table>
Total sales during the three-month period ended September 30, 2023 were above the comparable period ended September 30, 2022, but sales during the nine-month and twelve-month periods ended September 30, 2023 still lagged behind the comparable periods ended September 30, 2022.
Finished goods produced increased steadily from approximately&nbsp;$3.3 million&nbsp;to&nbsp;$4 million&nbsp;and further to&nbsp;$5.3 million&nbsp;during the first, second and third quarters of 2023, respectively. The Company aims to produce finished goods with an approximate sales value of&nbsp;$6 million&nbsp;per quarter, as it implements and optimizes recent investments to increase its production capacity.&nbsp;Third quarter&nbsp;production was approximately&nbsp;89%&nbsp;of this objective.
As the work to increase production output to meet demand continues, the backlog of orders increased to approximately&nbsp;$8.9 million&nbsp;as of September 30, 2023, which is an increase from approximately&nbsp;$8 million&nbsp;as of June 30, 2023 and a significant increase from approximately&nbsp;$2.5 million&nbsp;as of December 31, 2022.

ImmuCell Announces Preliminary, Unaudited Sales Results For Q3 2023; Sees Q3 Revenue $5.4M Vs 4.8M YoY

Health Care

ImmuCell Announced That It Recently Submitted The Chemistry, Manufacturing And Controls Technical Section For Re-Tain To The FDA

ImmuCell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCC#NASDAQ">ICCC</a>) reported quarterly losses of $(0.18) per share. This is a 100 percent decrease over losses of $(0.09) per share from the same period last year. The company reported $3.53 million in sales this quarter. This is a 8.50 percent decrease over sales of $3.86 million the same period last year.

ImmuCell Q2 EPS $(0.18) Down From $(0.09) YoY, Sales $3.53M Down From $3.86M YoY

Comments

ImmuCell

Vendite allo scoperto

ImmuCell (NASDAQ:ICCC) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO